• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.

作者信息

Breder Ikaro, Wolf Vaneza Lira W, Soares Alexandre A S, de Carvalho Luiz Sergio F, Kimura-Medorima Sheila T, Cintra Riobaldo M, Barreto Joaquim, Munhoz Daniel B, Cunha Jessica S, Bonilha Isabella, Coelho-Filho Otavio R, Quinaglia Thiago, Nadruz Wilson, Guerra-Junior Gil, Muscelli Elza, Sposito Andrei C

机构信息

Laboratory of Vascular Biology and Atherosclerosis. University of Campinas, Campinas, SP, Brazil.

College of Nursing, University of Campinas, Campinas, SP, Brazil.

出版信息

Diabetes Metab. 2022 Mar;48(2):101304. doi: 10.1016/j.diabet.2021.101304. Epub 2021 Nov 19.

DOI:10.1016/j.diabet.2021.101304
PMID:34808345
Abstract
摘要

相似文献

1
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.达格列净在短期内可降低2型糖尿病合并动脉粥样硬化疾病患者的肥胖程度并增加脂联素水平：一项活性对照随机试验。
Diabetes Metab. 2022 Mar;48(2):101304. doi: 10.1016/j.diabet.2021.101304. Epub 2021 Nov 19.
2
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.达格列净对 2 型糖尿病患者心房颤动的影响：来自 DECLARE-TIMI 58 试验的见解。
Circulation. 2020 Apr 14;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183. Epub 2020 Jan 27.
3
Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.达格列净：一种用于治疗糖尿病的钠-葡萄糖协同转运蛋白2抑制剂。
J Pharm Pract. 2016 Apr;29(2):165-71. doi: 10.1177/0897190014566308. Epub 2015 Jan 21.
4
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.评估钠-葡萄糖共转运蛋白 2 抑制剂达格列净对 2 型糖尿病合并非酒精性脂肪性肝病患者肝脂肪变性和纤维化的影响：应用瞬时弹性成像技术。
Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2.
5
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.达格列净对 2 型糖尿病患者肾脏疾病发生和进展的影响：DECLARE-TIMI 58 随机试验分析。
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10.
6
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.达格列净治疗2型糖尿病期间能量平衡的代偿性变化：一项随机双盲、安慰剂对照、交叉试验（ENERGIZE）——研究方案
BMJ Open. 2017 Jan 27;7(1):e013539. doi: 10.1136/bmjopen-2016-013539.
7
Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.评估达格列净对2型糖尿病患者左心室舒张功能影响的随机对照试验：IDDIA试验
Circulation. 2021 Feb 2;143(5):510-512. doi: 10.1161/CIRCULATIONAHA.120.051992. Epub 2020 Nov 13.
8
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.达格列净单药及联合沙格列汀降低蛋白尿的效果及在 2 型糖尿病合并慢性肾脏病患者中的血糖控制效果（DELIGHT）：一项随机、双盲、安慰剂对照试验。
Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13.
9
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.达格列净抑制 SGLT-2 减少组织钠含量：一项随机对照试验。
Cardiovasc Diabetol. 2018 Jan 4;17(1):5. doi: 10.1186/s12933-017-0654-z.
10
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.达格列净与既往心肌梗死的 2 型糖尿病患者的心血管结局
Circulation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996. Epub 2019 Mar 18.

引用本文的文献

1
Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.选择性SGLT2抑制剂恩格列净对2型糖尿病患者脂肪因子谱的体重无关改善作用
Cardiovasc Diabetol. 2025 Aug 31;24(1):355. doi: 10.1186/s12933-025-02917-z.
2
A precision medicine approach to metabolic therapy for breast cancer in mice.基于精准医学的小鼠乳腺癌代谢疗法。
Commun Biol. 2022 May 20;5(1):478. doi: 10.1038/s42003-022-03422-9.